Lakefront Biotherapeutics NV
LKFTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for LKFT. That does not mean none is planned.
Get an email about LKFT's next catalysts
Track Lakefront Biotherapeutics (LKFT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Filgotinib
Rheumatoid Arthritis
PTM filgotinib
Ulcerative Colitis
GLPG3970
Ulcerative Colitis
GLPG2737
Cystic Fibrosis
GLPG0974
Ulcerative Colitis
GLPG2222
Cystic Fibrosis
GLPG1837 dose 2
Cystic Fibrosis
GLPG1690
Systemic Sclerosis
GLPG1837 dose 1
Cystic Fibrosis
GLPG0259 oral capsule
Rheumatoid Arthritis
GLPG0634
Rheumatoid Arthritis
GLPG1205
Ulcerative Colitis
Lanraplenib
Sjogren's Syndrome
GLPG0259 (Part B)
Rheumatoid Arthritis
GLPG1837 dose 3
Cystic Fibrosis
GLPG1972
Osteoarthritis
GLPG3667
Systemic Lupus Erythematosus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Filgotinib | Phase 3 | Rheumatoid Arthritis | - | - |
PTM filgotinib | Phase 3 | Ulcerative Colitis | - | - |
GLPG3970 | Phase 2 | Ulcerative Colitis | - | - |
GLPG2737 | Phase 2 | Cystic Fibrosis | - | - |
GLPG0974 | Phase 2 | Ulcerative Colitis | - | - |
GLPG2222 | Phase 2 | Cystic Fibrosis | - | - |
GLPG1837 dose 2 | Phase 2 | Cystic Fibrosis | - | - |
GLPG1690 | Phase 2 | Systemic Sclerosis | - | - |
GLPG1837 dose 1 | Phase 2 | Cystic Fibrosis | - | - |
GLPG0259 oral capsule | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG0634 | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1205 | Phase 2 | Ulcerative Colitis | - | - |
Lanraplenib | Phase 2 | Sjogren's Syndrome | - | - |
GLPG0259 (Part B) | Phase 2 | Rheumatoid Arthritis | - | - |
GLPG1837 dose 3 | Phase 2 | Cystic Fibrosis | - | - |
GLPG1972 | Phase 2 | Osteoarthritis | - | - |
GLPG3667 | Phase 2 | Systemic Lupus Erythematosus | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Lakefront Biotherapeutics NV's drug pipeline?→
CatalystAlert tracks 17 drug candidates in Lakefront Biotherapeutics NV's (LKFT) pipeline across Phase 3, Phase 2. Its lead program is Filgotinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Lakefront Biotherapeutics NV's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Lakefront Biotherapeutics NV (LKFT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LKFT biotech catalysts?→
Add LKFT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lakefront Biotherapeutics NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.